Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I
Recruiting
Observational Study
Migraine Disorders
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 45
- Sex
- Any
- Study type
- Observational
- Participants needed
- 108 (estimated)
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan. Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Migraine with or without aura diagnosis according to ICHD-3 criteria
* \<8 migraine days per month
* Be able to read, write and understand instructions.
* Have internet access and mail address
* Signing of the informed consent
Exclusion Criteria:
* Active preventive treatmen…
Contacts